INTRODUCTION
Diabetes is one of the most commonly occurring diseases in both developed countries and in middle-and low-income countries.
According to the International's Diabetes Federation Diabetes Atlas [1, 2] These numbers reflect the growing economic burden on healthcare providers due to diabetes.
A recent systematic review of the global evidence on the costs of type 2 diabetes demonstrated that the costs of treating diabetes increase over time and with disease severity. Direct costs were found to be higher than indirect costs and to be particularly high in Western countries, such as the USA [2] .
A Canadian study demonstrated that costs were particularly high after the first year of diagnosing diabetes and reached C$3785-3826 (Canadian dollars). These costs increased substantially for older patients and for patients who eventually died during the follow-up. After accounting for baseline co-morbidities, costs were primarily incurred through inpatient acute hospitalizations, physician visits, prescription medications, and assistive devices [5] . Similar results have been found in other countries, including the USA and Europe [6] [7] [8] [9] [10] [11] .
In order to decrease costs and improve patients' outcomes it is important to understand the different effects of co-morbidities, complication, and various interventions on the costs of treating patients with diabetes. For example, chronic renal injury significantly raises the costs of treating patients with diabetes [12] [13] [14] . Also, it is important to assess the relative impact of higher HbA1C levels on medical costs as this guides the choice of cost-effective interventions in the spectrum of diabetic patients failing to achieve their HbA1c goals.
Maccabi Healthcare Services (MHS) is the second largest primary healthcare insurer and provider in Israel. This health maintenance organization (HMO) serves 25% of the total population in Israel, with approximately 2 million members. In a study assessing diabetes mellitus costs in MHS, diabetes accounted for 3.5% of the total medical costs for both men and women [15] .
The aim of this study was to evaluate the 
RESULTS
The diabetes registry included 99,017 patients, of whom 54% (53,283) were male and 72% were in the age group of 45-75 years. The mean and median costs of treating a patient with diabetes for 1 year was 14,250 and 4420 CU, respectively.
The main driver of cost was hospitalization, which accounted for 56% of the total spending on patients with diabetes. Additional costs included physician fees (11%) and all medications for treating diabetes (16%). The median annual medical costs for men and women were 4046 and 4839 CU, respectively.
Costs increased significantly with age ( Fig. 1 Table 1 , costs for both patients with controlled diabetes and poorly controlled diabetes increased by age in a similar fashion.
Additional co-morbidity increased costs in both groups, but this variable was more significant in patients with poorly controlled diabetes. In patients with poorly controlled diabetes, the median costs for those with no costs, as seen in Table 2 . Kidney injury and kidney disease increased significantly with age (Fig. 4) . Costs were significantly impacted by kidney disease, particularly in patients with kidney injury stage C and D (Fig. 5) Similar to our results, the cost of patients with micro-and macrovascular complications was fourfold higher than that of patients who did not have complications associated with diabetes [18] . In a study assessing medical costs of patients with diabetes in Spain, the medical care costs of patients with diabetes were 72.4%
higher than those for patients without diabetes [19] . Based on patient data compiled in this Spanish database, hospitalization of patients We demonstrated a significant impact of co-morbidities on the medical costs of patients with diabetes. Costs increased by threefold in patients with diabetes with three co-morbidities compared to patients with no co-morbidities in well-controlled patients with diabetes. The increase was 3.6-fold higher in patients with uncontrolled diabetes. These results are comparable to data from reported from other countries [9, 10, 13, 17, [20] [21] [22] . and physical activity [24] [25] [26] [27] . This may explain why cost assessment goes beyond the decrease of HbA1c level. Identifying these patients in an early stage and implementing multifaceted programs intervening in kidney function decline may offer a significant cost-effective intervention for patients with diabetes. This benefit seems to be pronounced in the younger population, as these patients are expected to remain in MHS for many additional years, with each year contributing to increased costs. Further study is warranted in this area.
The study has several limitations. This was a retrospective observational study. Therefore, all information relied on the completeness of the medical records of routine clinical visits.
Clinical events may not have been captured in full. It is possible that some co-morbidities were not recorded and that laboratory data were missing at various time-points.
CONCLUSION
The results of this study show that direct costs of patients with diabetes insured by MHS are higher than the costs of patients without diabetes insured by MHS. The major attributes of costs were hospitalizations and renal disease. In poorly controlled patients [HbA1c 8.0-8.99%
(64-74 mmol/mol) and patients with HbA1c [9.0% (75 mmol/mol)] the effect of HbA1c level on costs was limited. These findings suggest that it is cost effective to identify patients with diabetes early in the course of the disease and to direct efforts at preventing renal deterioration and hospitalizations.
